INVESTOR ALERT: Class Action Lawsuit Against Omnicell, Inc. Announced by Glancy Binkow & Goldberg LLP

Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of a class (the “Class”) comprising purchasers of the securities of Omnicell, Inc. (“Omnicell” or the “Company”) (NASDAQ:OMCL) between May 2, 2014 and March 2, 2015, inclusive (the “Class Period”).

Please contact Lesley Portnoy at 888-773-9224 or 310-201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

Omnicell provides automation and business information solutions designed to enable hospitals and long-term healthcare facilities to acquire, manage, dispense and administer medications and medical-surgical supplies. The Complaint alleges that defendants made false and/or misleading statements or failed to disclose material adverse facts, including: (1) the existence of a “side letter” arrangement with a Company customer for certain discounts and Company products that were to be provided at no cost, but which were not reflected in the final invoices paid by the customer; (2) that the Company lacked adequate internal controls over financial reporting; and (3), as a result of the foregoing, that the Company’s financial statements were materially false and misleading at all relevant times.

On March 2, 2015, the Company disclosed in a regulatory filing that Omnicell is unable to timely file its Annual Report on Form 10-K for the year ended December 31, 2014, and intends to file the Form 10-K within fifteen calendar days of the original due date. According to the Company, “additional time is required by the Company to investigate a notice received on February 27, 2015 from a Company employee alleging, among other matters, the existence of a ‘side letter’ arrangement with a Company customer for certain discounts and Company products that were to be provided at no cost, but which were not reflected in the final invoices paid by the customer.” Following this news, Omnicell shares fell $2.14 per share, or more than 6%, on March 3, 2015.

If you are a member of the Class described above, you may move the Court no later May 18, 2015, to serve as lead plaintiff, if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, at 310-201-9150, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.